Data from Farxiga Phase III DECLARE-TIMI 58 trial shows it significantly helped to reduce the progression of kidney disease in patients with type 2 diabetes.
Kiersten Combs is a member of the US Leadership Team (USLT) at AstraZeneca working closely with the pharmaceutical company’s BioPharmaceuticals Business Unit Leadership Team. In this role, Kiersten leads the US Cardiovascular and Metabolic Disease (CVMD) team and is responsible for the strategic direction, selling strategy and performance of the cardiovascular and diabetes business units. During her 15 years with AstraZeneca, Kiersten has served in various roles across many areas of the business, both in the US and globally, starting in supply chain and commercial operations. She has held marketing leadership roles for BRILINTA, CRESTOR, and EPANOVA and has held sales leadership roles in both the Respiratory and Diabetes organizations. Kiersten is a graduate of Cornell University with a BS in Business Management and Marketing.